NASDAQ:BVXV

BiondVax Pharmaceuticals - BVXV Stock Forecast, Price & News

$2.11

-0.06 (-2.76%)

(As of 03/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $2.10
▼
$2.19
50-Day Range: $2.10
▼
$3.06
52-Week Range: $2.03
▼
$19.65

Volume: 10,698 shs
Average Volume: 25,777 shs
Market Capitalization: $3.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

BiondVax Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.36% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.40
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.30) to ($0.20) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.23 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for BiondVax Pharmaceuticals.

3.0

Short Interest

Percentage of Shares Shorted
2.36% of the outstanding shares of BiondVax Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
BiondVax Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BiondVax Pharmaceuticals has recently increased by 13.92%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BiondVax Pharmaceuticals does not currently pay a dividend.
Dividend Growth
BiondVax Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BVXV.

1.9

News and Social Media Coverage

News Sentiment
BiondVax Pharmaceuticals has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for BiondVax Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for BVXV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BiondVax Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.03% of the stock of BiondVax Pharmaceuticals is held by insiders.

1.3

Earnings and Valuation

Earnings Growth
Earnings for BiondVax Pharmaceuticals are expected to grow in the coming year, from ($0.30) to ($0.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BiondVax Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BiondVax Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BiondVax Pharmaceuticals has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BiondVax Pharmaceuticals (NASDAQ:BVXV) Stock

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Stock News Headlines

March 26, 2023 | marketwatch.com

BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants

March 25, 2023 | americanbankingnews.com

BiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated by Analysts at StockNews.com

March 28, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast

March 19, 2023 | americanbankingnews.com

BiondVax Pharmaceuticals (NASDAQ:BVXV) Earns Hold Rating from Analysts at StockNews.com

March 16, 2023 | finance.yahoo.com

BiondVax to Present at BIO-Europe Spring

March 6, 2023 | finance.yahoo.com

IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman

March 3, 2023 | finance.yahoo.com

IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes

February 2, 2023 | finance.yahoo.com

BiondVax Presenting at BIO CEO & Investor Conference

March 28, 2023 | Investor Place Media (Ad)

The "King Of Quants" sees 10X potential...

Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...

January 25, 2023 | benzinga.com

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study

January 25, 2023 | benzinga.com

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19

January 23, 2023 | markets.businessinsider.com

BiondVax Pharma: In Vivo Data Shows NanoAb Virtually Prevents COVID-19 In Hamsters

January 23, 2023 | finance.yahoo.com

BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate

January 23, 2023 | it.tmcnet.com

BiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

January 23, 2023 | finance.yahoo.com

BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

January 15, 2023 | benzinga.com

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical Needs

January 6, 2023 | benzinga.com

BiondVax's Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

January 6, 2023 | finance.yahoo.com

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

January 5, 2023 | finance.yahoo.com

BiondVax to Present at Biotech Showcase 2023

December 30, 2022 | finance.yahoo.com

BiondVax CEO Issues Letter to Shareholders

December 21, 2022 | finance.yahoo.com

Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)

December 16, 2022 | msn.com

Why Biondvax Pharmaceuticals Stock Is Getting Obliterated During Friday's Trading Session

December 13, 2022 | finanznachrichten.de

BiondVax Pharmaceuticals Ltd.: BiondVax Regains Nasdaq Compliance

December 13, 2022 | finance.yahoo.com

IBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.

December 12, 2022 | finance.yahoo.com

BiondVax Regains Nasdaq Compliance

December 8, 2022 | finance.yahoo.com

BVXV: Positive Preclinical Results for Inhaled COVID-19 NanoAb…

December 6, 2022 | finance.yahoo.com

Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Company Calendar

Last Earnings: 3/28/2022
Today: 3/27/2023
Next Earnings (Estimated): 3/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BVXV
CUSIP: N/A
CIK: 1611747
Web: www.biondvax.com
Phone: 9723029302529
Fax: 972-8930-2531
Employees: 15
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($4.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,850,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -230.46%
Return on Assets: -35.35%

Debt

Debt-to-Equity Ratio: 5.92
Current Ratio: 5.76
Quick Ratio: 5.76

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.23 per share
Price / Book: 0.40

Miscellaneous

Outstanding Shares: 1,870,000
Free Float: 1,755,000
Market Cap: $3.95 million
Optionable: Not Optionable
Beta: 2.49

Key Executives

Amir Reichman
Chief Executive Officer & Director

Elad Mark
Chief Operating Officer

Uri Ben-Or
Chief Financial Officer

Tamar Ben-Yedidia
Chief Science Officer

Dalit Weinstein Fischer
Head-Technical, Research & Development

Key Competitors

View All Competitors

BVXV Stock - Frequently Asked Questions

How have BVXV shares performed in 2023?: BiondVax Pharmaceuticals' stock was trading at $2.96 on January 1st, 2023. Since then, BVXV shares have decreased by 28.7% and is now trading at $2.11.
View the best growth stocks for 2023 here.
When is BiondVax Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our BVXV earnings forecast.
How were BiondVax Pharmaceuticals' earnings last quarter?: BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced its quarterly earnings data on Monday, March, 28th. The company reported ($2.70) earnings per share for the quarter, missing the consensus estimate of ($0.90) by $1.80.
When did BiondVax Pharmaceuticals' stock split?: Shares of BiondVax Pharmaceuticals reverse split before market open on Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of BiondVax Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?: (BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.
What is BiondVax Pharmaceuticals' stock symbol?: BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."
How do I buy shares of BiondVax Pharmaceuticals?: Shares of BVXV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BiondVax Pharmaceuticals' stock price today?: One share of BVXV stock can currently be purchased for approximately $2.11.
How much money does BiondVax Pharmaceuticals make?: BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $3.95 million. The company earns $-12,850,000.00 in net income (profit) each year or ($4.04) on an earnings per share basis.
How can I contact BiondVax Pharmaceuticals?: BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for the company is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at j.phillipson@biondvax.com, or via fax at 972-8930-2531.

This page (NASDAQ:BVXV) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BiondVax Pharmaceuticals - BVXV Stock Forecast, Price & News

BiondVax Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About BiondVax Pharmaceuticals (NASDAQ:BVXV) Stock

BVXV Stock News Headlines

BVXV Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BVXV Stock - Frequently Asked Questions

Overall MarketRank^™